February 14, 2017 - 7:01 p.m.
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
February 08, 2017 - 7:18 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Printer Friendly Version 
February 07, 2017 - 4:04 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Printer Friendly Version 
February 07, 2017 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Printer Friendly Version 
January 24, 2017 - 5:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Printer Friendly Version 
January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
January 10, 2017 - 9:01 a.m.
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Printer Friendly Version 
January 03, 2017 - 4:31 p.m.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Printer Friendly Version 
NASDAQ (US Dollar)
$69.94
 Stock is Up 0.57 (0.82%)
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote